Its inclusion in the vector for subthalamic glutamic acid decarboxylase (GAD) gene therapy in a Parkinson’s disease rat model35 paved the way for approval by the US Food and Drug Administration (FDA) to be part of a human gene therapy clinical trial for Parkinson’s disease, which proved to be safe some years later.36 The gene discussed is GAD1; the disease is Parkinson disease.